Advertisement

Neurological Sciences

, Volume 37, Issue 2, pp 165–179 | Cite as

Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review

  • Timothy Vollmer
  • Lynn Huynh
  • Caroline Kelley
  • Philip Galebach
  • James Signorovitch
  • Allitia DiBernardo
  • Rahul Sasane
Review Article

Abstract

Patients with multiple sclerosis (MS) experience varying rates of brain volume (BV) loss ranging from 0.5 to 1.5 % per year. In addition, 66 % of patients with MS experience cognitive impairment, resulting in impact on daily activities. A systematic literature review (2003–2013) was conducted to identify all studies reporting a relationship between whole BV measures and selected patient outcomes measuring cognition, including the Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test (PASAT) and MS Functional Composite (MSFC) scores. We identified 18 studies reporting associations between whole BV and cognitive outcomes. Six studies (33 %) examined the association between BV and SDMT; all six studies reported that BV loss (BVL) was significantly associated with a decline in SDMT scores (all p < 0.05). Among 14 studies (78 %) that examined the association between BV and PASAT scores, 12 (86 %) found a significant relationship between BVL and lower PASAT scores (all p < 0.05). Of the seven studies (39 %) that looked at BV and MSFC, six studies (86 %) found BVL significantly associated with lower MSFC scores (all p < 0.05). Our study demonstrated that BVL is associated with declines in cognition in MS patients across several cognition measures. The results of this study suggest that BV is a critical component of disease activity and progression in MS and has implications for treatment decisions to minimize BVL and preserve cognitive functioning.

Keywords

Multiple sclerosis Patient outcomes Brain volume loss Cognition Systematic literature review 

Notes

Acknowledgments

Lynn Huynh, Philip Galebach, and Caroline Kelley contributed to the acquisition, analysis, and interpretation of the data, manuscript development, and approval of the final submitted version. James Signorovitch, Rahul Sasane, Allitia DiBernardo, and Timothy Vollmer conceived and planned the work that led to the manuscript, provided substantive suggestions for revisions, and approved the final submitted version. Dr. Vollmer has received consulting fees, and his institution has received a grant and consulting fee for his participation in the BRAVO study; is the medical director for the Rocky Mountain MS Center; he or his institution has received consultancy fees from Biogen-Idec, Teva, Hoffman-LaRoche, Accelerated Cure Project, Genzyme, Acorda, Novartis, Questor, Medscape, Xenoport, and Sanofi; his institution received fees/Grants from Teva, Biogen Idec, Genzyme, Ono, Eli Lilly, Novartis, BioMS, Orasi, Sanofi-Aventis, NIH, EMD Sorono, Acorda, Accelerated Cure Project, Hoffmann-LaRoche, Jensen Research, Janssen Pharmaceutical, MedImmune, Delta Quest, and Roche/Genentech. He is a co-holder of a patent with Teva Pharmaceuticals.

Compliance with ethical standards

Conflict of interest

Lynn Huynh, Caroline Kelley, Phil Galebach, and James Signorovitch are employees of Analysis Group, Inc., a consulting company that has received research Grants from Novartis Pharmaceuticals Corporation. Rahul Sasane is an employee of Novartis Pharmaceuticals Corporation. Allitia DiBernardo was an employee of Novartis Pharmaceuticals Corporation at the time the study was conducted. Financial support for this study was provided by Novartis Pharmaceuticals Corporation.

References

  1. 1.
    Chaudhuri A (2013) Multiple sclerosis is primarily a neurodegenerative disease (Vienna, Austria: 1996). J Neural Transm 120(10):1463–1466. doi: 10.1007/s00702-013-1080-3 CrossRefPubMedGoogle Scholar
  2. 2.
    Gold R, Wolinsky JS, Amato MP, Comi G (2010) Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord 3(6):351–367. doi: 10.1177/1756285610385608 PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Dutta R, Trapp BD (2007) Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 68(22 suppl 3):S22–S31CrossRefPubMedGoogle Scholar
  4. 4.
    Weinshenker BG (1994) Natural history of multiple sclerosis. Ann Neurol 36(Suppl):S6–S11CrossRefPubMedGoogle Scholar
  5. 5.
    Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125(Pt 8):1676–1695CrossRefPubMedGoogle Scholar
  6. 6.
    Cohen JA, Rudick RA (2007) Multiple sclerosis therapeutics, 3rd edn. Taylor & Francis, New YorkCrossRefGoogle Scholar
  7. 7.
    Benedict RHB (2011) Cognitive dysfunction in multiple sclerosis. Clinical Bulletin Information for Health Professionals. National Multiple Sclerosis Society, Professional Resource Center. http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Clinical-Bulletin-Cognitive-Dysfunction-Benedict.pdf
  8. 8.
    Amato MP, Ponziani G, Siracusa G, Sorbi S (2001) Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 58(10):1602–1606CrossRefPubMedGoogle Scholar
  9. 9.
    Achiron A, Chapman J, Magalashvili D, Dolev M, Lavie M, Bercovich E, Polliack M, Doniger GM, Stern Y, Khilkevich O, Menascu S, Hararai G, Gurevich M, Barak Y (2013) Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study. PLoS One 8(8):e71058. doi: 10.1371/journal.pone.0071058 PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Achiron A, Polliack M, Rao SM, Barak Y, Lavie M, Appelboim N, Harel Y (2005) Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curves. J Neurol Neurosurg Psychiatry 76(5):744–749. doi: 10.1136/jnnp.2004.045518 PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Rao SM, Martin AL, Huelin R, Wissinger E, Khankhel Z, Kim E, Fahrbach K (2014) Correlations between MRI and information processing speed in MS: a meta-analysis. Mult Scler Int 2014:975803. doi: 10.1155/2014/975803 PubMedCentralPubMedGoogle Scholar
  12. 12.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj 339. doi: 10.1136/bmj.b2700
  13. 13.
    Benedict RH, Bruce J, Dwyer MG, Weinstock-Guttman B, Tjoa C, Tavazzi E, Munschauer FE, Zivadinov R (2007) Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult Scler 13(6):722–730. doi: 10.1177/1352458507075592 CrossRefPubMedGoogle Scholar
  14. 14.
    Benedict RH, Bruce JM, Dwyer MG, Abdelrahman N, Hussein S, Weinstock-Guttman B, Garg N, Munschauer F, Zivadinov R (2006) Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 63(9):1301–1306. doi: 10.1001/archneur.63.9.1301 CrossRefPubMedGoogle Scholar
  15. 15.
    Benedict RH, Ramasamy D, Munschauer F, Weinstock-Guttman B, Zivadinov R (2009) Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J Neurol Neurosurg Psychiatry 80(2):201–206. doi: 10.1136/jnnp.2008.148403 CrossRefPubMedGoogle Scholar
  16. 16.
    Benedict RH, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R (2004) Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol 61(2):226–230. doi: 10.1001/archneur.61.2.226 CrossRefPubMedGoogle Scholar
  17. 17.
    Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, Atzori M, Bernardi V, Barachino L, Rinaldi L, Perini P, Gallo P, Filippi M (2009) Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 66(9):1144–1150. doi: 10.1001/archneurol.2009.174 CrossRefPubMedGoogle Scholar
  18. 18.
    Furby J, Hayton T, Altmann D, Brenner R, Chataway J, Smith KJ, Miller DH, Kapoor R (2010) A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. J Neurol 257(9):1508–1516. doi: 10.1007/s00415-010-5563-y CrossRefPubMedGoogle Scholar
  19. 19.
    Furby J, Hayton T, Anderson V, Altmann D, Brenner R, Chataway J, Hughes R, Smith K, Miller D, Kapoor R (2008) Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler 14(8):1068–1075. doi: 10.1177/1352458508093617 CrossRefPubMedGoogle Scholar
  20. 20.
    Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Hunter K, Tozer DJ, Miller DH, Kapoor R (2009) Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. J Neurol 256(3):427–435. doi: 10.1007/s00415-009-0110-4 CrossRefPubMedGoogle Scholar
  21. 21.
    Hildebrandt H, Hahn HK, Kraus JA, Schulte-Herbruggen A, Schwarze B, Schwendemann G (2006) Memory performance in multiple sclerosis patients correlates with central brain atrophy. Mult Scler 12(4):428–436CrossRefPubMedGoogle Scholar
  22. 22.
    Ingle GT, Stevenson VL, Miller DH, Thompson AJ (2003) Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 126(Pt 11):2528–2536. doi: 10.1093/brain/awg261 CrossRefPubMedGoogle Scholar
  23. 23.
    Jasperse B, Vrenken H, Sanz-Arigita E, de Groot V, Smith SM, Polman CH, Barkhof F (2007) Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis. Neuroimage 38(3):529–537. doi: 10.1016/j.neuroimage.2007.07.056 CrossRefPubMedGoogle Scholar
  24. 24.
    Locatelli L, Zivadinov R, Grop A, Zorzon M (2004) Frontal parenchymal atrophy measures in multiple sclerosis. Mult Scler 10(5):562–568CrossRefPubMedGoogle Scholar
  25. 25.
    Marrie RA, Fisher E, Miller DM, Lee JC, Rudick RA (2005) Association of fatigue and brain atrophy in multiple sclerosis. J Neurol Sci 228(2):161–166. doi: 10.1016/j.jns.2004.11.046 CrossRefPubMedGoogle Scholar
  26. 26.
    Mineev KK, Prakhova LN, Il’ves AG, Kataeva GV, Petrov AM, Reznikova TN, Pozdnyakov AV, Stolyarov ID (2009) Characteristics of neurological and cognitive status in patients with multiple sclerosis in relation to the location and volumes of demyelination foci and the severity of brain atrophy. Neurosci Behav Physiol 39(1):35–38. doi: 10.1007/s11055-008-9086-2 CrossRefPubMedGoogle Scholar
  27. 27.
    Sastre-Garriga J, Ingle GT, Chard DT, Cercignani M, Ramio-Torrenta L, Miller DH, Thompson AJ (2005) Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain 128(Pt 6):1454–1460. doi: 10.1093/brain/awh498 CrossRefPubMedGoogle Scholar
  28. 28.
    Sastre-Garriga J, Ingle GT, Chard DT, Ramio-Torrenta L, Miller DH, Thompson AJ (2004) Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. Neuroimage 22(1):353–359. doi: 10.1016/j.neuroimage.2004.02.008 CrossRefPubMedGoogle Scholar
  29. 29.
    Shiee N, Bazin PL, Zackowski KM, Farrell SK, Harrison DM, Newsome SD, Ratchford JN, Caffo BS, Calabresi PA, Pham DL, Reich DS (2012) Revisiting brain atrophy and its relationship to disability in multiple sclerosis. PLoS One 7(5):e37049. doi: 10.1371/journal.pone.0037049 PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Lazeron RH, Boringa J, Schouten M, Uitdehaag BM, Bergers E, Lindeboom J, Eikelenboom M, Scheltens P, Barkhof F, Polman C (2005) Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. Mult Scler 11(5):524–531CrossRefPubMedGoogle Scholar
  31. 31.
    Batista S, Zivadinov R, Hoogs M, Bergsland N, Heininen-Brown M, Dwyer MG, Weinstock-Guttman B, Benedict RH (2012) Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol 259(1):139–146CrossRefPubMedGoogle Scholar
  32. 32.
    Amato MP, Portaccio E, Goretti B, Zipoli V, Battaglini M, Bartolozzi ML, Stromillo ML, Guidi L, Siracusa G, Sorbi S (2007) Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 64(8):1157–1161CrossRefPubMedGoogle Scholar
  33. 33.
    Amato MP, Razzolini L, Goretti B, Stromillo ML, Rossi F, Giorgio A, Hakiki B, Giannini M, Pastò L, Portaccio E (2013) Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study. Neurology 80(19):1728–1733CrossRefPubMedGoogle Scholar
  34. 34.
    Amato M, Bartolozzi M, Zipoli V, Portaccio E, Mortilla M, Guidi L, Siracusa G, Sorbi S, Federico A, De Stefano N (2004) Neocortical volume decrease in relapsing–remitting MS patients with mild cognitive impairment. Neurology 63(1):89–93CrossRefPubMedGoogle Scholar
  35. 35.
    Amato M, Hakiki B, Goretti B, Rossi F, Stromillo M, Giorgio A, Roscio M, Ghezzi A, Guidi L, Bartolozzi M (2012) Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology 78(5):309–314CrossRefPubMedGoogle Scholar
  36. 36.
    Deloire M, Ruet A, Hamel D, Bonnet M, Brochet B (2010) Early cognitive impairment in multiple sclerosis predicts disability outcome several years later. Mult Scler 16(5):581–587. doi: 10.1177/1352458510362819 CrossRefPubMedGoogle Scholar
  37. 37.
    Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, Hamalainen P, Hartung HP, Krupp L, Penner IK, Reder AT, Benedict RH (2012) Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). Mult Scler 18(6):891–898. doi: 10.1177/1352458511431076 PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Akbar N, Honarmand K, Kou N, Feinstein A (2011) Validity of a computerized version of the symbol digit modalities test in multiple sclerosis. J Neurol 258(3):373–379. doi: 10.1007/s00415-010-5760-8 CrossRefPubMedGoogle Scholar
  39. 39.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis an expanded disability status scale (EDSS). Neurology 33(11):1444CrossRefPubMedGoogle Scholar
  40. 40.
    Lee MA, Smith S, Palace J, Matthews PM (1998) Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging. Brain 121(Pt 11):2095–2102CrossRefPubMedGoogle Scholar
  41. 41.
    Tauhid S, Chu R, Sasane R, Glanz B, Neema M, Miller J, JKim G, Signorivich J, Healy B, Chitnis T, Weiner H, Bakshi R (2014) Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. Paper presented at the ACTRIMS-ECTRIMS, Boston, MAGoogle Scholar
  42. 42.
    Li DK, Held U, Petkau J, Daumer M, Barkhof F, Fazekas F, Frank JA, Kappos L, Miller DH, Simon JH, Wolinsky JS, Filippi M, Sylvia Lawry Centre for MSR (2006) MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 66(9):1384–1389. doi: 10.1212/01.wnl.0000210506.00078.5c CrossRefPubMedGoogle Scholar
  43. 43.
    Sormani MP, Arnold DL, De Stefano N (2014) Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 75(1):43–49CrossRefPubMedGoogle Scholar
  44. 44.
    Calabrese M, De Stefano N, Atzori M, Bernardi V, Mattisi I, Barachino L, Morra A, Rinaldi L, Romualdi C, Perini P, Battistin L, Gallo P (2007) Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 64(10):1416–1422. doi: 10.1001/archneur.64.10.1416 CrossRefPubMedGoogle Scholar
  45. 45.
    Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH (2002) Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 125(Pt 2):327–337CrossRefPubMedGoogle Scholar
  46. 46.
    Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Bruck W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM (2011) Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365(23):2188–2197. doi: 10.1056/NEJMoa1100648 PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Frohman E, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief M, Stuve O, Racke M, Steinman L, Weiner H (2006) Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 63(4):614–619CrossRefPubMedGoogle Scholar
  48. 48.
    Rudick R, Fisher E, Lee J-C, Simon J, Jacobs L (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 53(8):1698CrossRefPubMedGoogle Scholar
  49. 49.
    Simon J, Li D, Traboulsee A, Coyle P, Arnold D, Barkhof F, Frank J, Grossman R, Paty D, Radue E (2006) Standardized MR imaging protocol for multiple sclerosis: consortium of MS Centers consensus guidelines. Am J Neuroradiol 27(2):455–461PubMedGoogle Scholar
  50. 50.
    Sumowski JF, Rocca MA, Leavitt VM, Riccitelli G, Comi G, DeLuca J, Filippi M (2013) Brain reserve and cognitive reserve in multiple sclerosis: what you’ve got and how you use it. Neurology 80(24):2186–2193. doi: 10.1212/WNL.0b013e318296e98b PubMedCentralCrossRefPubMedGoogle Scholar
  51. 51.
    Losseff N, Wang L, Lai H, Yoo D, Gawne-Cain M, McDonald W, Miller D, Thompson A (1996) Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain J Neurol 119(6):2009–2019CrossRefGoogle Scholar
  52. 52.
    Fisher E, Rudick R, Cutter G, Baier M, Miller D, Weinstock-Guttman B, Mass M, Dougherty D, Simonian N (2000) Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 6(6):373–377CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2015

Authors and Affiliations

  • Timothy Vollmer
    • 1
  • Lynn Huynh
    • 2
  • Caroline Kelley
    • 2
  • Philip Galebach
    • 2
  • James Signorovitch
    • 2
  • Allitia DiBernardo
    • 3
  • Rahul Sasane
    • 3
  1. 1.Department of NeurologyUniversity of Colorado DenverAuroraUSA
  2. 2.Analysis Group, Inc.BostonUSA
  3. 3.Novartis Pharmaceuticals CorporationEast HannoverUSA

Personalised recommendations